ClinicalTrials.gg
Drug

Docetaxel clinical trials

Also written Taxotere, RP56976, HB1801 and Docefrez.

Includes 3 studies of Liposomal Docetaxel and 3 studies of Nanoparticle Albumin-Bound Docetaxel.

studies test it
1,164
open now
100
in phase 3
189
first study started
1993
Related medicines add 8 studies

Counted the way a researcher would: Docetaxel with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.

This browser remembers your choice.

How each study uses Docetaxel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Docetaxel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
14 May 1996 · TAXOTERE · NDA 020449 (FDA, Drugs@FDA)
European Union
27 Nov 1995 · Taxotere · EMEA/H/C/000073 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Docetaxel
855
Docecad
39
Taxotere Injection Concentrate
38
TXT
22
Docetaxel (Taxotere)
10

Brand

Taxotere
362
Docefrez
9
BEIZRAY
1

Development codes

RP56976
63
HB1801
10
NSC-628503
3
XRP6976
3
BH011
1

In one entry with another drug

Given together, or one or the other

docetaxel and cisplatin
9
Docetaxel, Cisplatin
5
Gemcitabine and Docetaxel
5
docetaxel, cisplatin, fluorouracil
4
FLOT
3
Docetaxel plus cisplatin
3
docetaxel and capecitabine
3
Docetaxel, Oxaliplatin
3

Studies by the year they started

1,159 studies that test it; most in 2004 (99)

Studies that test Docetaxel, by start year
YearStudies
19931
19941
19953
19962
199711
199817
199935
200027
200140
200255
200376
200499
200588
200670
200783
200863
200944
201041
201135
201227
201331
201430
201529
201630
201719
201827
201916
202022
202123
202218
202329
202423
202525
202619

By phase

A phase 1/2 study counts in both.

Early Phase 1
3
Phase 1
227
Phase 2
831
Phase 3
189
Phase 4
11
No phase
22

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 203 · Other 961

Sanofi (51) · National Cancer Institute (NCI) (31) · M.D. Anderson Cancer Center (29) · Alliance for Clinical Trials in Oncology (23) · Hoffmann-La Roche (20) · Dana-Farber Cancer Institute (19) · SWOG Cancer Research Network (19) · Memorial Sloan Kettering Cancer Center (18)

Often tested with

Tested in the same studies.

Cisplatin (189) · Gemcitabine (122) · Carboplatin (104) · Fluorouracil (95) · Capecitabine (90) · Oxaliplatin (74) · Cyclophosphamide (71) · Doxorubicin (64)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 78 phase 3 studies under way

Docetaxel is the comparator. A study of two new drugs counts under both.

  • 4Paclitaxel · Fudan University, Henan Cancer Hospital · next primary completion Jun 2028
  • 3Sacituzumab tirumotecan · Merck Sharp & Dohme LLC · next primary completion May 2027
  • 3Desoxyepothilone B · Beijing Biostar Pharmaceuticals Co., Ltd., Sun Yat-sen University
  • 2Tambotatug pelitecan · MediLink Therapeutics (Suzhou) Co., Ltd. · next primary completion Dec 2027
  • 2Datopotamab deruxtecan · Daiichi Sankyo, AstraZeneca · next primary completion Jan 2029
  • 2Trastuzumab rezetecan · Jiangsu HengRui Medicine Co., Ltd. · next primary completion Jun 2027
  • 2Sacituzumab govitecan · Gilead Sciences, National Cancer Institute (NCI) · next primary completion Dec 2030
  • 2Pembrolizumab · Merck Sharp & Dohme LLC, National Cancer Institute (NCI) · next primary completion May 2027
Reaching primary completion within a year · 34, 8 in phase 3

Studies that test Docetaxel, phase 3 first.

Studies

Open first, then newest update. How each study uses Docetaxel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 1,164

See all 1,164 studies that test Docetaxel →

Given beside what is tested · 673 — Docetaxel is usual care or a partner of the new treatment

Showing 20 of 673.

As the comparator · 256 — what is tested is compared with Docetaxel

Showing 20 of 256.

Codes

What other systems call Docetaxel · ClinicalTrials.gg INT006647

  • MeSH (NLM) D000077143DocetaxelConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 15H5577CQDDOCETAXELConfirmed FDA, NLM, Wikidata
  • RxNorm 72962Confirmed FDA, Wikidata
  • Wikidata Q27126905docetaxel trihydrateConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C1526DocetaxelConfirmed FDA, Wikidata

Also registered as docetaxel anhydrous (UNII 699121PHCA · RxNorm 1299922).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.